Factors associated with day 28 response: univariate analysis
| Factor . | N . | Day 28 CR/PR (%) . | OR (95% CI) . | P . | Day 28 CR (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| All patients | 251 | 189 (75) | 129 (51) | ||||
| Trial | .11 | .78 | |||||
| 0302 | 103 | 83 (81) | 54 (52) | ||||
| 0802 | 148 | 106 (72) | 75 (51) | ||||
| Age, y | .51 | .24 | |||||
| <18 | 10 | 8 (80) | 6 (60) | ||||
| 18-34 | 43 | 29 (67) | 19 (44) | ||||
| 35-49 | 56 | 41 (73) | 24 (43) | ||||
| ≥50 | 142 | 111 (78) | 80 (56) | ||||
| Donor type | .07 | .29 | |||||
| HLA-matched sibling | 91 | 72 (79) | 53 (58) | ||||
| Other related | 18 | 17 (94) | 11 (61) | ||||
| URD | 120 | 83 (69) | 55 (46) | ||||
| Mismatched URD | 4 | 2 (50) | 1 (25) | ||||
| UCB | 18 | 15 (83) | 9 (50) | ||||
| Conditioning | .32 | .32 | |||||
| Myeloablative | 161 | 118 (73) | 79 (49) | ||||
| Reduced-intensity | 90 | 71 (79) | 50 (56) | ||||
| Minnesota aGVHD risk | .02 | .01 | |||||
| SR | 194 | 153 (79) | 108 (56) | ||||
| HR | 57 | 36 (63) | 21 (37) | ||||
| AREG | <.01 | .01 | |||||
| First quartile, <19.8 | 62 | 58 (94) | 39 (63) | ||||
| Second quartile, 19.8-33.7 | 62 | 46 (74) | 34 (55) | ||||
| Third quartile, 33.8-70.2 | 64 | 49 (77) | 35 (55) | ||||
| Fourth quartile, >70.2 | 63 | 36 (57) | 21 (33) | ||||
| Continuous variable, OR per doubling in AREG at onset | 0.67 (0.56-0.79) | <.01 | 0.76 (0.65-0.89) | <.01 | |||
| AREG, optimal cut point, pg/mL | <.01 | .01 | |||||
| <33 | 120 | 102 (85) | 72 (60) | ||||
| ≥33 | 131 | 87 (66) | 57 (44) |
| Factor . | N . | Day 28 CR/PR (%) . | OR (95% CI) . | P . | Day 28 CR (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| All patients | 251 | 189 (75) | 129 (51) | ||||
| Trial | .11 | .78 | |||||
| 0302 | 103 | 83 (81) | 54 (52) | ||||
| 0802 | 148 | 106 (72) | 75 (51) | ||||
| Age, y | .51 | .24 | |||||
| <18 | 10 | 8 (80) | 6 (60) | ||||
| 18-34 | 43 | 29 (67) | 19 (44) | ||||
| 35-49 | 56 | 41 (73) | 24 (43) | ||||
| ≥50 | 142 | 111 (78) | 80 (56) | ||||
| Donor type | .07 | .29 | |||||
| HLA-matched sibling | 91 | 72 (79) | 53 (58) | ||||
| Other related | 18 | 17 (94) | 11 (61) | ||||
| URD | 120 | 83 (69) | 55 (46) | ||||
| Mismatched URD | 4 | 2 (50) | 1 (25) | ||||
| UCB | 18 | 15 (83) | 9 (50) | ||||
| Conditioning | .32 | .32 | |||||
| Myeloablative | 161 | 118 (73) | 79 (49) | ||||
| Reduced-intensity | 90 | 71 (79) | 50 (56) | ||||
| Minnesota aGVHD risk | .02 | .01 | |||||
| SR | 194 | 153 (79) | 108 (56) | ||||
| HR | 57 | 36 (63) | 21 (37) | ||||
| AREG | <.01 | .01 | |||||
| First quartile, <19.8 | 62 | 58 (94) | 39 (63) | ||||
| Second quartile, 19.8-33.7 | 62 | 46 (74) | 34 (55) | ||||
| Third quartile, 33.8-70.2 | 64 | 49 (77) | 35 (55) | ||||
| Fourth quartile, >70.2 | 63 | 36 (57) | 21 (33) | ||||
| Continuous variable, OR per doubling in AREG at onset | 0.67 (0.56-0.79) | <.01 | 0.76 (0.65-0.89) | <.01 | |||
| AREG, optimal cut point, pg/mL | <.01 | .01 | |||||
| <33 | 120 | 102 (85) | 72 (60) | ||||
| ≥33 | 131 | 87 (66) | 57 (44) |
Bold values are statistically significant.